Alizyme completes Colal-Pred trial dosing

Alizyme (LSE:AZM) completed dosing in its 37-patient Phase II trial of Colal-Pred to treat mild-to-moderate ulcerative colitis. Data are expected in February, and Phase III testing is expected later i...